Madrigal Pharmaceuticals
MDGL
135 hedge funds and large institutions have $1.19B invested in Madrigal Pharmaceuticals in 2019 Q1 according to their latest regulatory filings, with 23 funds opening new positions, 50 increasing their positions, 31 reducing their positions, and 23 closing their positions.
200% more funds holding in top 10
Funds holding in top 10: 1 → 3 (+2)
131% more call options, than puts
Call options by funds: $79.4M | Put options by funds: $34.3M
61% more repeat investments, than reductions
Existing positions increased: 50 | Existing positions reduced: 31
17% more capital invested
Capital invested by funds: $1.01B → $1.19B (+$174M)
3.02% more ownership
Funds ownership: 58.36% → 61.37% (+3%)
0% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 23
1% less funds holding
Funds holding: 136 → 135 (-1)
Top Buyers
| 1 |
AC
Armistice Capital
New York
|
+$52.8M |
| 2 |
HM
HealthCor Management
New York
|
+$25.2M |
| 3 |
MWNA
Marshall Wace North America
New York
|
+$17.6M |
| 4 |
ACA
Avoro Capital Advisors
New York
|
+$10.6M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$5.59M |
Top Sellers
| 1 |
JP Morgan Chase
New York
|
-$48.3M |
| 2 |
Morgan Stanley
New York
|
-$6.28M |
| 3 |
Citigroup
New York
|
-$6.09M |
| 4 |
AG
Artal Group
Luxembourg
|
-$4.35M |
| 5 |
PC
Pier Capital
Stamford,
Connecticut
|
-$4.24M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
151
Bessemer Group
Woodbridge,
New Jersey
| – | -$116K | -1,033 | Closed |
|
|
GTC
152
Ghost Tree Capital
New York
| – | -$101K | -900 | Closed |
|
|
MAM
153
Meeder Asset Management
Dublin,
Ohio
| – | -$63K | -557 | Closed |
|
154
SEI Investments
Oaks,
Pennsylvania
| – | -$100K | -465 | Closed |
|
|
ER
155
Enlightenment Research
Miami,
Florida
| – | -$23K | -200 | Closed |
|
|
GT
156
Glenmede Trust
Philadelphia,
Pennsylvania
| – | -$7 | -68 | Closed |
|
MDGL Hedge Fund Activity: Q1 2019 in Review
135 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Madrigal Pharmaceuticals (MDGL) for Q1 2019, worth a combined $1.19B — up 17% from $1.01B a quarter earlier.
Fund positioning in MDGL was balanced in Q1 2019: 23 funds opened new positions, 23 closed out, 50 added to existing stakes and 31 trimmed.
The largest buyer was Armistice Capital, opening a new position worth an estimated $52.8M. The largest seller was JP Morgan Chase, cutting an estimated $48.3M.
- 135 institutional investors held Madrigal Pharmaceuticals (MDGL) as of Q1 2019, down from 136 in Q4 2018.
- Funds reported $1.19B of Madrigal Pharmaceuticals stock for Q1 2019, up 17% quarter-over-quarter.
- 23 funds opened new Madrigal Pharmaceuticals positions in Q1 2019 and 23 closed out, a net change of 0 holders.
- The largest Madrigal Pharmaceuticals buyer in Q1 2019 was Armistice Capital, an estimated $52.8M added.
- The largest Madrigal Pharmaceuticals seller in Q1 2019 was JP Morgan Chase, an estimated $48.3M sold.
Based on aggregated 13F filings for Q1 2019.